Literature DB >> 28857477

Human placenta mesenchymal stem cells promote axon survival following optic nerve compression through activation of NF-κB pathway.

Mira Park1, Hyung Chul Kim1, Okjoon Kim2, Helen Lew1.   

Abstract

Different damage factors are known to trigger cell death in the optic nerves. Use of mesenchymal stem cells is a possible treatments option for traumatic optic nerve injury due to their ability to secrete protective cytokines and recovery factors. In this study, we investigated the neuroprotective effects of human placenta-derived mesenchymal stem cells (hPMSCs) using an established optic nerve compression model and model of R28 cells that were exposed to hypoxia. Forty percent of axon death was seen in induced in vivo optic nerve injury model (p < .05), and 70% of R28 cells exposed to cobalt chloride (CoCl2 ), leading to hypoxia, underwent apoptosis (p < .05). After intravenous injection of hPMSCs into tail vein, there was 25% improvement of axon survival in vivo (p < .05). R28 cells incubated with hPMSCs after exposure to hypoxic condition resulted in 50% increased cell survival compared with R28 cells without hPMSC exposure (p < .05), suggesting the active release of multiple factors related to cell survival. In addition, we found that Nf-κb protein mediates neuroprotection pathway via up-regulation of target proteins regulated by hPMSCs. Therefore, we assert that Nf-κb was one of the mediator proteins in a recovery pathway induced by hPMSCs. In conclusion, these indicate that transactivation of Nf-κb protein has a critical role in recovery mechanism by hPMSCs. We suggest that hPMSCs have abilities to recover neuronal damages by up-regulating the expression of genes associated with axon survival and can a better understanding of the possible role of hPMSCs in the treatment modalities of optic nerve injury.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  NF-κB; axon; mesenchymalstem cells; optic nerve; placenta

Mesh:

Substances:

Year:  2017        PMID: 28857477     DOI: 10.1002/term.2561

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  6 in total

Review 1.  Neuro-protection and neuro-regeneration of the optic nerve: recent advances and future directions.

Authors:  Kimberly K Gokoffski; Micalla Peng; Basheer Alas; Phillip Lam
Journal:  Curr Opin Neurol       Date:  2020-02       Impact factor: 5.710

2.  TGFβ-Treated Placenta-Derived Mesenchymal Stem Cells Selectively Promote Anti-Adipogenesis in Thyroid-Associated Ophthalmopathy.

Authors:  Hyun-Ah Shin; Mira Park; Jasvinder Paul Banga; Helen Lew
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

3.  Hypoxia-Preconditioned Placenta-Derived Mesenchymal Stem Cells Rescue Optic Nerve Axons Via Differential Roles of Vascular Endothelial Growth Factor in an Optic Nerve Compression Animal Model.

Authors:  Heejung Kwon; Mira Park; Sarmila Nepali; Helen Lew
Journal:  Mol Neurobiol       Date:  2020-06-10       Impact factor: 5.682

4.  Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.

Authors:  Mira Park; J Paul Banga; Gi Jin Kim; MinYoung Kim; Helen Lew
Journal:  Stem Cell Res Ther       Date:  2019-08-09       Impact factor: 6.832

5.  Human Pluripotent Stem Cell-Derived Neural Progenitor Cells Promote Retinal Ganglion Cell Survival and Axon Recovery in an Optic Nerve Compression Animal Model.

Authors:  Mira Park; Hyun-Mun Kim; Hyun-Ah Shin; Seung-Hyun Lee; Dong-Youn Hwang; Helen Lew
Journal:  Int J Mol Sci       Date:  2021-11-20       Impact factor: 5.923

6.  UBA2 activates Wnt/β-catenin signaling pathway during protection of R28 retinal precursor cells from hypoxia by extracellular vesicles derived from placental mesenchymal stem cells.

Authors:  Kyungmin Koh; Mira Park; Eun Soo Bae; Van-An Duong; Jong-Moon Park; Hookeun Lee; Helen Lew
Journal:  Stem Cell Res Ther       Date:  2020-10-02       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.